Breaking News
February 18, 2019 - How Inactivity and Junk Food Can Harm Your Brain
February 18, 2019 - Diabetes tops common conditions for frequent geriatric emergency patients
February 18, 2019 - Longer-lived sperm produces offspring with healthier lifespans
February 18, 2019 - New dental adhesive prevents tooth decay around orthodontic brackets
February 18, 2019 - New eHealth tool shows potential to improve quality of asthma care
February 18, 2019 - New Australian initiative helps emergency clinicians to improve patient care
February 17, 2019 - Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from the FDA for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria
February 17, 2019 - Researchers identify faulty ‘brake’ that interferes with heart muscle’s ability to contract and relax
February 17, 2019 - Support from trusted adults can reduce risk of dying in suicidal teens, finds study
February 17, 2019 - Heart attack awareness improved since 2008
February 17, 2019 - Exercise gives a better brain boost to older men than women
February 17, 2019 - New research disproves previous assumptions of how looks influence personality
February 17, 2019 - Cannabis use as a teenager linked to depression later in life
February 17, 2019 - Sinks by Toilets in ICU Patient Rooms Harbor Harmful Bacteria
February 17, 2019 - Cancer cells’ plasticity makes them harder to stop
February 17, 2019 - Young cannabis users have increased risk of depression and suicidal behavior
February 17, 2019 - Tasmanian Devils Likely to Survive Cancer Scourge
February 17, 2019 - Neoadjuvant PD-1 blockade seems effective in glioblastoma
February 17, 2019 - Personal, social factors play role in enabling sustainable return to work after ill health
February 17, 2019 - Mouse studies show ‘inhibition’ theory of autism wrong
February 17, 2019 - Study shows how neuroactive steroids inhibit activity of pro-inflammatory proteins
February 17, 2019 - Use of liver grafts from older donors decreased despite better outcomes in recipients
February 17, 2019 - MUSC researchers discover new mechanism for a class of anti-cancer drugs
February 17, 2019 - HPV misconceptions are causing women to miss smear tests
February 17, 2019 - Sanofi and Regeneron Offer Praluent (alirocumab) at a New Reduced U.S. List Price
February 17, 2019 - Researchers say auditory testing can identify children for autism screening
February 17, 2019 - New method analyzes how single biological cells react to stressful situations
February 17, 2019 - WVU gynecologic oncologist investigates novel treatment for cervical and vaginal cancers
February 17, 2019 - ADHD diagnoses poorly documented
February 17, 2019 - Majority of gender minority youth do not identify with traditional sexual identity labels
February 17, 2019 - AbbVie, Teneobio enter into strategic transaction to develop potential treatment for multiple myeloma
February 17, 2019 - Lower Birth Weight May Up Risk for Psychiatric Disorders
February 17, 2019 - Scientists identify reversible molecular defect underlying rheumatoid arthritis
February 17, 2019 - Moffitt researchers shed light on how CAR T cells function mechanistically
February 16, 2019 - Female Anatomy May Play Big Role in Sperm’s Success
February 16, 2019 - BMI may mediate inverse link between fiber intake, knee OA
February 16, 2019 - Movement impairments in autism can be reversed through behavioral training
February 16, 2019 - Studies address racial disparities in postpartum period and cardiovascular health
February 16, 2019 - Scientists implicate hidden genes in the severity of autism symptoms
February 16, 2019 - Decreased deep sleep linked to early signs of Alzheimer’s disease
February 16, 2019 - Neuroscientists show how the brain responds to texture
February 16, 2019 - Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
February 16, 2019 - What Can I Do About Sweating? (for Teens)
February 16, 2019 - Companies navigate dementia conversations with older workers
February 16, 2019 - Newly developed stem cell technologies show promise for treating PD patients
February 16, 2019 - Collaborative material research could advance self-assembling nanomaterials
February 16, 2019 - Researchers take major step in creating technology that mimics the human brain
February 16, 2019 - Erasing memories associated with cocaine use reduces drug seeking behavior
February 16, 2019 - Artificial intelligence can accurately predict prognosis of ovarian cancer patients
February 16, 2019 - Racial disparities in cancer deaths on the decline for America
February 16, 2019 - FDA authorizes new interoperable insulin pump for children, adults with diabetes
February 16, 2019 - Coexisting Medical Conditions, Smoking Explain PTSD-CVD Link
February 16, 2019 - Skin Cancer Screening: MedlinePlus Lab Test Information
February 16, 2019 - ‘Happiness’ exercises can boost mood in those recovering from substance use disorder
February 16, 2019 - Cell manipulation could soon halt or reverse aging
February 16, 2019 - Pumped Breast Milk Falls Short of Breastfed Version
February 16, 2019 - Men’s porn habits could fuel partners’ eating disorders, study suggests
February 16, 2019 - Rapid progression of age-related diseases may result from formation of vicious cycles
February 16, 2019 - Immune checkpoint molecule protects against future development of cancer
February 16, 2019 - New method produces hydrogels that have properties similar to cells’ environment
February 16, 2019 - $4.1 million funding for heart research on Valentine’s Day
February 16, 2019 - General anesthesia in early infancy unlikely to have lasting effects on developing brains
February 16, 2019 - New breakthroughs for muscular dystrophy research
February 16, 2019 - First Opinion: Embryo editing for higher IQ is a fantasy. Embryo profiling for it is almost here
February 16, 2019 - Vapers develop cancer-related gene deregulation as cigarette smokers
February 16, 2019 - Bringing Antimicrobial Susceptibility Testing (AST) to the Community
February 16, 2019 - Decolonization protocol after hospital discharge can prevent dangerous infections
February 16, 2019 - Children with ASD more likely to face maltreatment, study finds
February 16, 2019 - Study finds genetic vulnerability to use of menthol cigarettes
February 16, 2019 - Promising drug developed to rejuvenate muscle cells
February 16, 2019 - H-RT should be the standard of care for men with low risk prostate cancer, study shows
February 16, 2019 - New technique using patients’ own modified cells could help treat Crohn’s disease
February 16, 2019 - Therapeutic endoscopy has an expanding role in the treatment of IBD
February 16, 2019 - Blood clot discovery could lead to development of better treatments for blood diseases
February 16, 2019 - Intervention can increase exclusive breastfeeding rates
February 16, 2019 - New project explores how gaming technologies can help cancer patients communicate better
February 16, 2019 - Catalyst Biosciences Presents Updated Data from Its Phase 2/3 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors at the 12th Annual EAHAD Congress
February 16, 2019 - Rerouting nerves during amputation reduces phantom limb pain before it starts
February 16, 2019 - A Hormone Produced When We Exercise Might Help Fight Alzheimer’s
February 16, 2019 - Millions of British people breathe toxic air travelling to GPs
Havard University grants license to Beam Therapeutics to develop new base editing technology

Havard University grants license to Beam Therapeutics to develop new base editing technology

image_pdfDownload PDFimage_print

Harvard University has granted a worldwide license to Beam Therapeutics, Inc., to develop and commercialize a suite of revolutionary DNA base editing technologies for the treatment of human disease.

The versatile platform of base editing technologies was invented by David R. Liu, PhD, Professor of Chemistry and Chemical Biology, and visionary postdoctoral fellows and graduate students in his Harvard laboratory.

“We developed programmable molecular machines that go to a target site of our choosing in the genomic DNA of a cell and directly convert one base to another base without making a double-stranded break in the DNA,” said Liu, who is a cofounder of Beam.

The licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the targeting scope of base editing, opens up a wide range of human genetic conditions to the therapeutic promise of genome editing.

“Base editing represents a powerful platform for addressing a large class of genetic diseases that are more difficult to tackle with other methods of genome editing,” said Vivian Berlin, Director of Business Development in Harvard’s Office of Technology Development (OTD).

“Genome-editing and base editing technologies exemplify the continuous, vital contributions of Harvard’s researchers to biomedical innovation, and the opportunities such advances create for economic development and societal benefit,” said Isaac T. Kohlberg, Senior Associate Provost and Chief Technology Development Officer at Harvard. “The opportunity here is not only to tackle disease but perhaps to fundamentally change the practice of medicine.”

Beam announced today that it has raised up to $87 million in Series A financing led by F-Prime Capital Partners and ARCH Venture Partners.

Game-changing innovation

In the human genome, tens of thousands of variations in the sequence of DNA bases — As, Cs, Gs, and Ts — are known to contribute to disease. The majority of disease-associated human DNA variations consist of point mutations — locations in the genome where a single base pair has been replaced by another. That’s true for mutations that are associated with conditions including neurodegenerative diseases, metabolic diseases, blood diseases, losses of vision or hearing, and thousands of other known diseases with a genetic component.

Genome editing technologies using the CRISPR platform in combination with enzymes like Cas9 and Cpf1 have shown great promise for adjusting genes through insertions or deletions of multiple nucleotides, but have had more difficulty correcting single nucleotides cleanly and efficiently. The suite of Harvard technologies licensed to Beam uniquely meets that need.

Liu likens it to having the right tool for the job. Existing methods of genome editing that attempt to correct point mutations, including those using the CRISPR/Cas9 system, use CRISPR as molecular scissors to make double-stranded breaks and then rely on an introduced DNA template to guide correction. Double-stranded breaks within the cell, however, trigger end-joining processes that reconnect the broken ends but introduce stochastic insertions and deletions while doing so. As a result, the precise correction of point mutations typically has to compete with the generation of these other undesired byproducts. In addition, precise correction with CRISPR/Cas9 typically relies on cellular components that are absent in cells not actively dividing — that is, most cells in the body.

“Instead of precisely fixing a disease-driving mutation in a specific gene, cutting a target site more often disrupts the gene or creates a mixture of mutated variants of the gene,” explained Liu.

In contrast, the base editing methods developed in Liu’s Harvard lab use an engineered multi-component protein that includes a modified form of Cas9 to unzip a targeted portion of the DNA helix, opening up a small bubble in which to perform surgery on a single base, without causing double-stranded breaks in DNA. Liu’s base editors then directly convert the target base from the mutated form to the corrected form, and in some cases also enlist an additional protein component to prevent the cell from undoing the correction. Meanwhile, the engineered Cas9 nicks the unedited strand of DNA, prompting the cell to mend that second strand with a base that complements the corrected base. The result is a double swap that permanently changes an entire base pair (such as A* T) to a different base pair (such as G* C). Liu’s team reported the development of various base editors in Nature in 2016, Nature Biotechnology in February 2017, Nature Communications in June 2017, Science Advances in August 2017, Nature in October 2017, and Nature in February 2018.

“Over the past year and a half, we’ve greatly expanded the scope of base editing technologies,” said Liu, “broadening their targeting scope, improving their target DNA specificity, and creating new classes of base editors that could have a substantial impact on the treatment of genetic diseases.”

“That’s the ultimate goal: in an unmodified organism, whether it’s a human or a plant or an animal, to be able to change a DNA base to another DNA base at will, cleanly, and with high efficiency,” Liu said. “If we can get there, I think the potential for societal benefit is high.”

Spurring rapid development

“Our goal is to see this innovation develop into transformative treatments for the widest possible range of human diseases,” said OTD’s Berlin. “Licensing the commercial rights to a new startup ensures a rapid mobilization of resources to fully develop and exploit the technology in this field.”

To that end, the agreement with Beam Therapeutics stipulates particular diligence obligations by which the company must demonstrate its progress toward developing products. It also stipulates mechanisms by which a third party can propose to develop a therapeutic product, either in partnership with Beam (via a collaboration or sublicense) or through a separate agreement with the University, if that program is not of serious interest to Beam. Meanwhile, academic science remains entirely unhindered; the University always retains the rights of researchers to continue to use the intellectual property for educational and not-for-profit research purposes, whether at Harvard or elsewhere. The intellectual property is also available for licensing on a non-exclusive basis for industrial research purposes.

Under the terms of the agreement, the University will receive a multimillion-dollar upfront licensing payment from Beam Therapeutics, with additional terms confidential. The compensation acknowledges the value Harvard has created through its pioneering research and will support continued scientific discovery and innovation on campus.

Tagged with:

About author

Related Articles